Heron Therapeutics Inc Dossier - Source-backed chat

Heron Therapeutics Inc

HRTXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.43

Intrinsic Value

No headline value published yetWe haven't published a headline intrinsic value for this company yet. Our data-reliability standards weren't met. Method estimates are shown for reference.

Market Price $0.36Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $67.6M

Enterprise Value $188.5M

Shares Outstanding 189.9M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Heron Therapeutics is transitioning from a high-burn development-stage biotech into a commercially disciplined, cash-flow-generative specialty pharmaceutical company. The investment thesis centers on the rapid commercial acceleration of its Acute Care franchise (ZYNRELEF and APONVIE) driven by key structural catalysts, including a permanent product-specific J-Code for ZYNRELEF and its inclusion in the Non-Opioid Policy for Pain Relief (NOPAIN). While the Oncology franchise faces near-term headwinds from a recent adverse patent ruling on CINVANTI, the company's settlement with Baxter and disciplined cost management support its reaffirmed 2026 guidance of $173M to $183M in net product sales and positive Adjusted EBITDA of $10M to $20M. At a depressed valuation near its 52-week low, the stock offers a highly asymmetric risk-reward profile as the company approaches operational profitability.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$2.00

Mean target$2.00

High · most bullish analyst$2.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$1.0015%

The bear case assumes that the recent Delaware District Court ruling invalidating certain CINVANTI patents accelerates generic entry, severely eroding Heron's oncology supportive care revenue base. Simultaneously, the commercial rollout of ZYNRELEF and APONVIE underperforms expectations due to execution delays in the Q3 2026 sales force expansion or slower-than-expected hospital formulary adoption. Under this scenario, Heron fails to achieve positive Adjusted EBITDA in 2026, leading to continued cash burn and potential dilution from future capital raises.

Base CaseCentral scenario

$2.5060%

The base case assumes Heron successfully executes its commercial strategy, meeting its reaffirmed full-year 2026 guidance of $173M to $183M in net product sales and $10M to $20M in Adjusted EBITDA. Acute Care growth remains robust (+30% YoY), offsetting flat-to-declining oncology revenues. The Q3 2026 sales force expansion is completed on schedule, and temporary gross margin pressures normalize as higher-cost CINVANTI inventory is worked through over the next two quarters. Valuation multiples recover toward historical averages as the company achieves sustained positive Adjusted EBITDA.

Bull CaseUpside scenario

$4.0025%

The bull case assumes rapid adoption of ZYNRELEF and APONVIE following the planned Q3 2026 sales force expansion, with elective surgical volumes rebounding strongly. ZYNRELEF benefits from frictionless reimbursement under the new J-Code (J0668), driving deep penetration into hospital outpatient departments and ambulatory surgery centers. CINVANTI successfully defends its market share through the REIGNITE program, and the company beats the high end of its 2026 guidance, achieving net product sales over $185M and Adjusted EBITDA exceeding $20M, leading to significant multiple expansion.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong Acute Care franchise momentum, with Q1 2026 net revenues up 32% year-over-year, led by ZYNRELEF (+27%) and APONVIE (+50%).
Favorable structural reimbursement tailwinds, including a permanent product-specific J-Code (J0668) for ZYNRELEF and inclusion in the NOPAIN policy.
Reaffirmed full-year 2026 guidance pointing to operational profitability, with net product sales of $173M to $183M and Adjusted EBITDA of $10M to $20M.
Disciplined cost management and a solid cash runway, ending Q1 2026 with $44.8M in cash, cash equivalents, and short-term investments.

Key Investment Risks

Legal and generic risks following the June 2026 Delaware District Court ruling that declared certain CINVANTI patent claims invalid.
Commercial execution risk associated with the planned sales force expansion in Q3 2026 and the onboarding of new accounts.
High leverage and debt service obligations, with total debt standing at approximately $141.6M as of Q1 2026.
Reimbursement and policy changes that could impact hospital procurement decisions and pricing power.

Thesis Invalidation Triggers

Failure to achieve positive Adjusted EBITDA by the end of fiscal year 2026.
A rapid decline in CINVANTI market share below 20% due to premature generic launches.
Quarterly ZYNRELEF demand unit growth slowing to single digits, indicating a failure of the J-Code and sales force expansion catalysts.
Cash and short-term investments falling below $25M, necessitating a highly dilutive equity raise.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.